Status:
NOT_YET_RECRUITING
Ketamine for Postherpetic Neuralgia With Depression
Lead Sponsor:
Huazhong University of Science and Technology
Conditions:
Depression Disorders
Herpetic Neuralgia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This clinical trial examines the antidepressant efficacy and safety of a single low-dose intravenous esketamine combined with oral duloxetine in patients with postherpetic neuralgia and depression (du...
Eligibility Criteria
Inclusion
- Diagnosed with herpetic neuralgia, with a disease course exceeding 1 month, and an HADS-D score ≥8 (15) upon admission.
- Diagnosed with depression based on the DSM-V and ICD-11 criteria.
- Aged between 18 and 65 years old.
- BMI \<30 kg/m².
Exclusion
- Unable to cooperate with questionnaires.
- Allergic to ketamine.
- History of other mental disorders such as anxiety.
- Severe hypertension and serious dysfunctions of heart, lung, liver, or kidney.
Key Trial Info
Start Date :
June 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06968624
Start Date
June 15 2025
End Date
June 1 2026
Last Update
June 3 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.